Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development Kumar Jeetendra | March 7, 2022 Basel, Switzerland, 07 March 2022 – Lonza has expanded its renowned human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a critical and rapidly expanding market need. Lots in a range of sizes are also now available with high-resolution HLA-type information, removing the requirement …
